Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10546716 | 0.87 | KDM4E (0.45) | ALDH1A1KMT2AMEN1KDM4EHPGD | |
| SCHEMBL10540170 | 0.86 | ALDH1A1 (0.44) | ALDH1A1KMT2AMEN1MAPTKDM4E | |
| SCHEMBL10545821 | 0.85 | APEX1 (0.46) | ALDH1A1KDM4EHPGDCASP3GLA | |
| SCHEMBL10540562 | 0.82 | KDM4E (0.41) | ALDH1A1KMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL10543598 | 0.82 | KDM4E (0.47) | ALDH1A1KMT2AMEN1MAPTKDM4E | |
| SCHEMBL9834136 | 0.82 | NQO2 (0.51) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL10540558 | 0.82 | KDM4E (0.48) | ALDH1A1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL9377904 | 0.82 | ALDH1A1 (0.42) | ALDH1A1KMT2AMEN1PDK2KDM4E | |
| SCHEMBL10544373 | 0.81 | KDM4E (0.40) | ALDH1A1KMT2AMEN1MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL10541711 | 0.80 | MDM2 (0.46) | ALDH1A1KMT2AMEN1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1222187-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMA (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6770639-B2 | CELL PROLIFERATIVE; AUTOIMMUNE DISEASES; ANTIALLERGENS; ANTIINFLAMMATORY AGENTS; ANTICANCER AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030166929-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
| US-6506769-B2 | Pyridine -imidazole, -thiazole or -oxazole derivatives; treating autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-1222187-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020016460-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001025238-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
| EP-0275888-B1 | Tricyclic benzimidazoles, process for their preparation and use as medicaments | BOEHRINGER MANNHEIM GMBH (DE) | 1994-04-06 | — | — | EP | disclosed |
| US-5116843-A | Anticoagulants, hypotensive agents and cardiovascular disorder | BOEHRINGER MANNHEIM GMBH (DE) | 1992-05-26 | — | — | US | disclosed |
| US-4954498-A | HYPOTENSIVE AGENTS, ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1990-09-04 | — | — | US | disclosed |
| EP-0275888-A2 | Tricyclic benzimidazoles, process for their preparation and use as medicaments | Roche Diagnostics GmbH (DE) | 1988-07-27 | — | — | EP | disclosed |
| US-4176184-A | CARDIOTONICS, HYPOTENSIVES, ANTITHROMBOTICS AND ANTIARRHYTHMICS | BOEHRINGER INGELHEIM GMBH (DE) | 1979-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016460-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | LTK, FRK, JAK1 | CA12 4047/4885CA1 1445/4885CA2 3174/4885 |
| US-20030166929-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | LTK, FRK, JAK1 | CA12 4047/4885CA1 1445/4885CA2 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.